GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
New Data Add To Confidence
Executive Summary
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
You may also be interested in...
Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
In Vivo takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities
Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
GemVax Seeks Revival Of Pancreatic Cancer Indication On ASCO Phase III Data
New Phase III pancreatic cancer results for GV1001, an immunotherapeutic peptide, were presented at ASCO, which GemVax hopes will revive the drug after its conditional approval in South Korea was canceled last year.